Affiliations: [a] Alexion Antibody Technologies, Inc., San Diego, CA, USA | [b] Alexion Pharmaceuticals, Inc., Cheshire, CT, USA | [c] Battelle Biomedical Research Center, Columbus, OH, USA
Correspondence:
[*]
Corresponding author: Katherine S. Bowdish, Alexion Antibody Technologies, Inc. 3985A Sorrento Valley Blvd., San Diego, CA, 92121, USA. Tel.: +1 858 361 6394; Fax: +1 858 350 7484; E-mail: [email protected].
Abstract: ALXN4100, a fully human antibody that binds to the protective antigen of anthrax toxin, was generated from a Fab isolated from a phage display library and was analyzed for its pharmacokinetic properties in rabbits and then used to protect rabbits from challenge with a lethal aerosol dose of Bacillus anthracis spores (≈322X LD50). All rabbits receiving 15 or 40 mg/kg of antibody 24 hours before challenge survived; survival of rabbits receiving 4 mg/kg either subcutaneously or intravenously was 80 or 90%, respectively. Susceptibility to anthrax disease appeared to be correlated with serum antibody concentration. This study indicates that ALXN4100 has the potential to be useful for prophylaxis of anthrax disease in humans.
Keywords: Monoclonal antibody, human antibody, therapeutic antibody, anthrax, spore challenge
